Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

Trial Profile

A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2019

At a glance

  • Drugs Lixisenatide (Primary) ; Insulin glulisine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms GetGoal-Duo-2
  • Sponsors Sanofi
  • Most Recent Events

    • 05 Oct 2018 Results of a propensity score-matched analysis to Compare LixiLan-L and GetGoal Duo-2 trials presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 31 Aug 2018 Biomarkers information updated
    • 15 Sep 2017 Results of exploratory analysis assessing if iGlarLixi is more effective and better tolerated than sequential injections of iGlar and Lixi using patient data from NCT02058160 and NCT01768559 trials presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top